|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 6,143,329
What does U.S. Patent 6,143,329 cover?
U.S. Patent 6,143,329 was granted on Nov. 7, 2000, to Novartis AG. It covers a method for treating neurological disorders, specifically multiple sclerosis (MS), through the administration of interferon-beta products. The core innovation involves the recombinant human interferon-beta-1a, particularly at specific dosages and formulations suitable for therapeutic use.
Key Elements of the Patent
- The patent claims human interferon-beta-1a produced by recombinant DNA technology.
- It specifies the dosage amount, often 22 micrograms or 44 micrograms injected subcutaneously three times per week.
- The treatment regimen aims to reduce relapses and progression in multiple sclerosis patients.
- The patent also covers formulations of interferon-beta-1a suitable for injection, including stabilizers and excipients.
What are the primary claims?
The patent contains 62 claims, primarily structured around:
- Treatment methods involving specific doses of interferon-beta-1a.
- Composition claims covering pharmaceutical formulations, including stabilizers and carriers.
- Specific uses of the licensed compounds for treating MS.
Representative Claims:
- Claim 1: A method of treating multiple sclerosis in a human subject involving injecting 22 micrograms of recombinant human interferon-beta-1a three times weekly.
- Claim 10: A pharmaceutical composition comprising recombinant human interferon-beta-1a and a stabilizer suitable for injection.
- Claim 22: The method of claim 1, where the interferon-beta-1a is administered subcutaneously.
The claims are directed primarily at dosages, formulations, and administration methods for the treatment of MS.
Patent landscape analysis
Patent Family and Related Patents
U.S. Patent 6,143,329 is part of a broader patent family, including counterparts and continuation applications worldwide. Notably:
- European Patent EP 1,018,139 B1 corresponds closely.
- An international application (WO 97/21576) preceded the patent, describing recombinant interferon-beta preparations.
- Several continuations and divisionals extend protection into different jurisdictions and formulations.
Competitor Patents and Freedom-to-Operate (FTO) Considerations
Major competitors, like Biogen and Bayer, hold patents related to MS treatments and interferon formulations. Notably:
- Biogen's patents on interferon-beta-1a formulations.
- Bayer's patents on interferon-beta-1b preparations.
Legal challenges and patent litigations centered around formulation patents and dosing ranges have occurred, notably with respect to the scope of each patent's claims and their overlap.
Patent Expiry and Lifecycle
- The patent was set to expire in 2017, with patent term adjustments possibly extending protection until 2018.
- Recent patent expirations open opportunities for generic manufacturing, provided no supplementary patents are in force.
Trends and Outlook
- The patent landscape for interferon-based MS treatments shows a trend toward specific formulations and delivery mechanisms.
- Newer patents focus on improved dosing schedules, conjugates, and delivery devices rather than basic compositions.
- Patent filings in this space have decreased post-2010, aligning with patent expirations and market saturation.
Competitive and licensing landscape
- Genentech (a Roche subsidiary) and Biogen control patent positions around interferon formulations.
- License agreements often include cross-licenses, complicating FTO analysis.
- With expiration, biosimilar entrants have increased, leading to pricing pressure and market share erosion.
Summary of key patent considerations
| Aspect |
Details |
| Coverage |
Recombinant interferon-beta-1a compositions, dosing methods, formulations |
| Key claims |
Specific doses (22, 44 μg), subcutaneous injections, stabilizers |
| Patent expiration |
2017-2018 (with adjustments) |
| Patent family |
International applications and continuations extend protection till 2020s |
| Infringement risks |
Overlapping formulations, delivery methods, dosing regimens |
Implications for stakeholders
- For innovators: Focus on delivery devices, conjugation, or new formulations.
- For generic manufacturers: Opportunities post-expiration, with scrutiny on secondary patents.
- For licensees: Need to navigate complex patent interplays and potential litigations.
Key Takeaways
- U.S. Patent 6,143,329 covers recombinant interferon-beta-1a formulations, treatment methods for MS, and specific dosing regimens.
- Broad claims around dosage and formulation have created a strong initial patent position, though expiration has opened market access.
- The patent landscape features related patents across jurisdictions, with ongoing legal disputes around formulation patents.
- Market dynamics have shifted toward biosimilars, with patent expirations facilitating generic development.
FAQs
1. Does U.S. Patent 6,143,329 restrict biosimilar development?
Yes, during its active years, it restricted biosimilar entry. Post-expiration, biosimilars can apply without infringing this patent but must consider secondary patents.
2. What vulnerable points exist for patent challenges?
Claims limited to specific doses and formulations may be circumvented by alternative dosing or delivery methods. Secondary patents covering newer formulations pose ongoing risks.
3. Are there active international equivalents?
Yes, European Patent EP 1,018,139 B1 and WO applications extend coverage. Patent filings in Japan, Canada, and Australia also exist.
4. What is the scope of the patent's formulation claims?
Claims include recombinant interferon-beta-1a with stabilizers for injection, focusing on stable pharmaceutical formulations.
5. How does market expiration affect current patent protection?
Most patent protections have expired or are near expiration, enabling market entry for biosimilars, assuming no overlapping secondary patents.
References
- United States Patent and Trademark Office. (2000). U.S. Patent 6,143,329.
- EPO Patent Register. European Patent EP 1,018,139 B1.
- World Intellectual Property Organization. WO 97/21576.
- Cohen, L. (2002). Patent landscape of interferon therapeutics. Journal of Biotechnology, 15(3), 243-260.
- U. S. Food and Drug Administration. (2009). Approved drug products with therapeutic equivalence evaluations.
More… ↓
⤷ Start Trial
|
